Clinical Trial Update: Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis [Phase 3]

View source ↗

Summary

Phase 3 trial update indicating completion of a study evaluating Zemplar Capsule (paricalcitol) for reducing serum intact parathyroid hormone (iPTH) levels in a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar Capsule (paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Kidney Disease | Phase 3 | Status: COMPLETED